Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

 Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

Merck’s Brenzys (biosimilar, etanercept) Receives Health Canada Approval for Multiple Indications

Shots:

  • Health Canada has approved Brenzys for new indications that include adults & pediatric patients (4-17yrs.) with PsO who are candidates for systemic therapy/ phototherapy, adult patients with PsA, and patients aged 4-17yrs. with JIA
  • The clinical efficacy and safety studies conducted in patients with RA demonstrate clinical comparability between Brenzys and the reference product. The extrapolation of these data supports the use of Brenzys in AS
  • Brenzys is a biosimilar referencing Enbrel, which is approved for use for PsO, PsA, and JIA in Canada. Brenzys received its first Health Canada approval in 2016 for the mod. to sev. RA in adults and AS and is administered via injection under the skin and should be used under the guidance and supervision of a physician

Click here ­to­ read full press release/ article | Ref: Newswire Canada| Image: Vancouver Sun

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post